Treatment with prasinezumab — an experimental therapy designed to stop toxic alpha-synuclein protein clumps from spreading through the brain — seems to slow the progression of motor symptoms in people with Parkinson’s disease. That’s according to the results of a new analysis that compared the findings of a…

TreeFrog Therapeutics’ investigational cell therapy restored motor function in a rat model of Parkinson’s disease, according to a recent presentation. The therapy, designed to replace the dopamine-producing nerve cells lost in Parkinson’s, involves transplanting a three-dimensional “microtissue” that contains the cells directly into the brain. Kevin Alessandri, PhD,…

The Syn-One test, which uses a skin biopsy to look for atypical clumps of the protein alpha-synuclein, may help both in confirming a diagnosis and guiding treatment decisions for people being evaluated for Parkinson’s disease, new data show. “Skin biopsies are minimally invasive and, our study showed, very effective…

AB-1005, an experimental gene therapy administered directly into the brain, helped ease motor symptoms in patients with moderate Parkinson’s disease, whereas it appeared to stabilize disease progression for those with mild disease in a small Phase 1 clinical trial. No serious safety issues were reported for the 11…